INTRODUCTION {#s1}
============

Gastric cancer (GC) is the 4^th^ most common malignant disease and the 2^nd^ most frequent cause of cancer-related deaths around the world \[[@R1]\]. GC is accepted as a pathophysiologically heterogeneous disease, which is associated with hematogenous metastasis, predominant lymphatic spread, or intra-abdominal spread \[[@R2]\]. There are approximately one million new cases annually worldwide and 850,000 deaths from GC, or about 12% deaths of all cancer \[[@R3]\]. GC is a multifactorial disease caused by environmental and lifestyle factors, other recognized risk factors include smoking, obesity, dietary factors, radiation, Helicobacter pylori infection, pernicious anemia and partial gastrectomy, etc. \[[@R4]\]. Early detection is possible with screening, but most GC patients are diagnosed at an inoperable advanced stage which requiring palliative chemotherapy \[[@R5]\]. The most widely used drugs as single agents for chemotherapy are fluorouracil, doxorubicin, cisplatin, mitomycin C, epirubicin, and etoposide, and newer chemotherapeutic agents include the taxanes, oxaliplatin oral fluoropyrimidines, and irinotecan \[[@R6]\]. Despite the advances achieved over the recent decades, the prognosis of patients with advanced GC (AGC) remains poor \[[@R7]\]. New chemotherapy regimens are desperately needed for the benefit of improving the dismal prognosis of AGC.

Currently, there is no globally accepted chemotherapy regimen for AGC, some are used as single agents, while others are used as part of combination regimens. Fluorouracil is one of the most widely used agents in the treatment of AGC, and it is a part of all the primary multidrug regimens that have been reported \[[@R8]\]. Fluorouracil monotherapy, as a standard treatment for AGC, is associated with manageable toxicity, a response rate of approximately 20%, and OS times of between 5\~7 months in phase III randomized studies \[[@R9]\]. Recently, capecitabine and S-1, belonging to oral fluoropyrimidines, are suggested to be more tolerable than fluorouracil; and both of them showed exhibit antitumor activity against AGC \[[@R10]--[@R12]\]. Capecitabine (Xeloda, F. Hoffmann--La Roche) is known as an oral fluoropyrimidine, which is designed to mimic a continuous infusion of fluorouracil, and it has shown good response rates in AGC patients when given as monotherapy or in combination with other agents in phase II studies \[[@R6]\]. Study has shown that replacing fluorouracil with capecitabine plus cisplatin avoids the need for continuous infusions and the combinations of two agents have few overlapping toxic effects \[[@R13]\]. S-1 is a novel oral fluoropyrimidine consisting of a tegafur (5-FU prodrug), 5-chloro-2, 4-dihydroxypyridine (the dihydropyrimidine dehydrogenase inhibitor) and potassium oxonate (suppresses the gastrointestinal toxicity of tegafur) \[[@R14]\]. In 2007, one phase III trials in Japan (the JCOG9912 trial) demonstrated that S-1 was not inferior to fluorouracil \[[@R15]\]. The other was the SPIRITS trial, which suggested that the combination therapy of S-1-plus-cisplatin was superior to S-1 monotherapy \[[@R12]\]. Since there are controversies in different studies,, no consensus has been reached on the optimal chemotherapy regimen in the treatment of AGG in terms of single drug chemotherapy regimen and multi-drug combination chemotherapy regimens based on fluorouracil, capecitabine and S-1.

Network meta-analysis is a relatively new statistical technique that gives access to compare both direct and indirect evidence, even when two of the interventions have not been directly compared \[[@R16]\]. Network meta-analysis can summarize randomized clinical trials (RTCs) of several different treatment strategies, and supply point estimates for their association with a given endpoint, together with an estimate of incoherence. Therefore, we performed a network meta-analysis to compare the short-term efficacies of different chemotherapy regimens in the treatment of AGC.

RESULTS {#s2}
=======

Baseline characteristics of included study {#s2_1}
------------------------------------------

Through electronic databases, 3791 relevant studies were initially identified. We excluded 684 studies for duplicates, 101 for non-human studies, 2420 for no relation to research topic. The remaining 586 articles were further excluded according to the following factors: 124 studies related to targeted therapy, 287 studies related to surgical treatment and 110 studies related to radiotherapy. Eventually, 35 RCTs, published between 1991 and 2014, were eligible for this network meta-analysis \[[@R11], [@R17]--[@R50]\]. These 35 RCTs altogether included 4555 GC patients treated with twenty-four chemotherapy regimens including cisplatin + fluorouracil (CF), docetaxel + cisplatin (DC), irinotecan + cisplatin (CI), cisplatin + capecitabine (CX), S-1 + cisplatin (S-1C), docetaxel + fluorouracil (DF), paclitaxel + fluorouracil (PF), fluorouracil + leucovorin (FL), docetaxel + oxaliplatin (DO), S-1 + irinotecan (S-1I), S-1 + paclitaxel (S-1P), etoposide + adriamycin + cisplatin (EAC), docetaxel + cisplatin + fluorouracil (DCF), etoposide + cisplatin + fluorouracil (ECF), fluorouracil + adriamycin + mitomycin (FAM), fluorouracil + adriamycin + methotrexate (FAMTX), etoposide + leucovorin + fluorouracil (ELF), fluorouracil + leucovorin + irinotecan (FLI), etoposide + cisplatin + capecitabine (ECX), fluorouracil + leucovorin + cisplatin (FLC), and cisplatin + etoposide + leucovorin + fluorouracil (CELF), and the majority of patients received CF and FAMTX chemotherapy regimens (Figure [1a](#F1){ref-type="fig"}-[1b](#F1){ref-type="fig"}). Of these 35 enrolled studies, 15 studies were from Caucasians, and 20 studies were from Asians; additionally, 29 studies were two-arm trials and 6 studies were three-arm trials. The baseline characteristics of included studies are displayed in Table [1](#T1){ref-type="table"}.

![Network diagram for 24 kinds of chemotherapy regimens in terms of DCR and ORR (DCR = disease control rate; ORR = overall response rate; A: cisplatin + fluorouracil; B: fluorouracil; C: S-1; D: capecitabine; E: docetaxel + cisplatin; F: irinotecan + cisplatin; G: cisplatin + capecitabine; H: S-1 + cisplatin; I: docetaxel + fluorouracil; J: paclitaxel + fluorouracil; K: fluorouracil + leucovorin; L: docetaxel + oxaliplatin; M: S-1 + irinotecan; N: S-1 + paclitaxel; O: etoposide + adriamycin + cisplatin; P: docetaxel + cisplatin + fluorouracil; Q: etoposide + cisplatin + fluorouracil; R: fluorouracil + adriamycin + mitomycin; S: fluorouracil + adriamycin + methotrexate; T: etoposide + leucovorin + fluorouracil; U: fluorouracil + leucovorin + irinotecan; V: etoposide + cisplatin + capecitabine; W: fluorouracil + leucovorin + cisplatin; X: cisplatin + etoposide + leucovorin + fluorouracil; a: DCR; b: ORR)\
The size of the nodes is proportional to the number of studies that evaluate each intervention, and the thickness of the lines is proportional to the frequency of each comparison in the network.](oncotarget-08-37896-g001){#F1}

###### The main baseline characteristics of included studies

  Author              Year   Country       Ethnicity    Number   Interventions   Outcomes               
  ------------------- ------ ------------- ------------ -------- --------------- ---------- --- --- --- ----------
  Wils JA             1991   Netherland    Caucasians   79       81              \~         R   S       ORR; DCR
  Kelsen D            1992   USA           Caucasians   30       30                         O   S       ORR
  Kim NK              1993   Korea         Asians       55       54              57         A   B   R   ORR; DCR
  Cocconi G           1994   Italy         Caucasians   85       52              \~         X   R       ORR; DCR
  Waters JS           1999   UK            Caucasians   121      116             \~         Q   S       ORR; DCR
  Ohkuwa M            2000   Japan         Asians       46       42                         A   O       ORR
  Vanhoefer U         2000   Netherland    Caucasians   81       85              79         A   S   T   ORR; DCR
  Bugat R             2003   France        Caucasians   74       72              \~         U   F       ORR; DCR
  Cocconi G           2003   Italy         Caucasians   98       97              \~         X   S       ORR; DCR
  Ohtsu A             2003   Japan         Asians       105      105             \~         A   B       ORR; DCR
  Bouche O            2004   France        Caucasians   45       45              44         K   U   W   ORR; DCR
  Moehler M           2005   Germany       Caucasians   56       58              \~         U   T       ORR; DCR
  Thuss-Patience PC   2005   Germany       Caucasians   45       45              \~         Q   I       ORR; DCR
  Park SH             2006   Korea         Asians       39       38              \~         J   I       ORR; DCR
  Sadighi S           2006   Iran          Asians       42       44                         Q   P       ORR
  Van CutsemE         2006   Belgium       Caucasians   224      221                        A   P       ORR; DCR
  Lutz MP             2007   Germany       Caucasians   33       48              46         B   K   W   ORR; DCR
  Roth AD             2007   Switzerland   Caucasians   40       41              38         Q   P   E   ORR; DCR
  Lee JL              2008   Korea         Asians       45       46                         C   D       ORR; DCR
  Nakashima K         2008   Japan         Asians       26       36                         F   H       ORR; DCR
  Popov IP            2008   Serbia        Caucasians   30       30                         B   O       ORR; DCR
  Kang YK             2009   Korea         Asians       137      139                        A   G       ORR
  Seol YM             2009   Korea         Asians       32       40                         H   G       ORR; DCR
  Yun JA              2009   Korea         Asians       44       45                         V   G       ORR; DCR
  Lim LH              2010   Korea         Asians       37       97              77         A   H   G   ORR
  Kim JA              2011   Korea         Asians       28       30                         E   U       ORR; DCR
  Komatsu Y           2011   Japan         Asians       47       48                         C   M       ORR; DCR
  Narahara H          2011   Japan         Asians       93       94                         C   M       ORR; DCR
  Mochiki E           2012   Japan         Asians       41       42                         H   N       ORR; DCR
  Nishikawa K         2012   Japan         Asians       19       13                         N   J       ORR; DCR
  Ocvirk J            2012   Slovenia      Caucasians   45       40                         Q   V       ORR; DCR
  Shitara K           2013   Japan         Asians       37       20                         H   G       ORR; DCR
  Wang X              2013   China         Asians       41       41                         C   N       ORR; DCR
  Kim YS              2014   Korea         Asians       38       39                         E   L       ORR; DCR
  Sugimoto N          2014   Japan         Asians       51       51                         N   M       ORR; DCR

Note: G:Group; DCR = disease control rate; ORR = overall response rate; A: cisplatin + fluorouracil; B: fluorouracil; C: S-1; D: capecitabine; E: docetaxel + cisplatin; F: irinotecan + cisplatin; G: cisplatin + capecitabine; H: S-1 + cisplatin; I: docetaxel + fluorouracil; J: paclitaxel + fluorouracil; K: fluorouracil + leucovorin; L: docetaxel + oxaliplatin; M: S-1 + irinotecan; N: S-1 + paclitaxel; O: etoposide + adriamycin + cisplatin; P: docetaxel + cisplatin + fluorouracil; Q: etoposide + cisplatin + fluorouracil; R: fluorouracil + adriamycin + mitomycin; S: fluorouracil + adriamycin + methotrexate; T: etoposide + leucovorin + fluorouracil; U: fluorouracil + leucovorin + irinotecan; V: etoposide + cisplatin + capecitabine; W:fluorouracil + leucovorin + cisplatin; X:cisplatin + etoposide + leucovorin + fluorouracil.

Pairwise meta-analysis for short-term efficacy of twenty-four chemotherapy regimens in the treatment of advanced gastric cancer {#s2_2}
-------------------------------------------------------------------------------------------------------------------------------

We carried out direct pairwise comparisons for the short-term efficacies of twenty-four chemotherapy regimens in the treatment of AGC, and the results suggested that the efficacies of fluorouracil, FAM and FAMTX chemotherapy regimens were relatively poorer in DCR of AGC patients when compared with CF regimen (fluorouracil: OR = 0.37, 95%CI = 0.17\~0.57; FAM: OR = 0.40, 95%CI = 0.02\~0.78; FAMTX: OR = 0.50, 95%CI = 0.17\~0.83) (Figure [2a](#F2){ref-type="fig"}). The efficacies of fluorouracil and FAMTX chemotherapy regimens were relatively poorer in ORR of AGC patients (fluorouracil: OR = 0.28, 95%CI = 0.11\~0.44; FAM: OR = 0.31, 95%CI = 0.03\~0.59), while CX chemotherapy regimens had better efficacy for AGC (OR = 1.85, 95%CI = 1.01\~2.69) (Figure [2b](#F2){ref-type="fig"}).

![Forest plots of traditional meta-analysis for 24 kinds of chemotherapy regimens in terms of DCR and ORR (DCR = disease control rate; ORR = overall response rate; A: cisplatin + fluorouracil; B: fluorouracil; C: S-1; D: capecitabine; E: docetaxel + cisplatin; F: irinotecan + cisplatin; G: cisplatin + capecitabine; H: S-1 + cisplatin; I: docetaxel + fluorouracil; J: paclitaxel + fluorouracil; K: fluorouracil + leucovorin; L: docetaxel + oxaliplatin; M: S-1 + irinotecan; N: S-1 + paclitaxel; O: etoposide + adriamycin + cisplatin; P: docetaxel + cisplatin + fluorouracil; Q: etoposide + cisplatin + fluorouracil; R: fluorouracil + adriamycin + mitomycin; S: fluorouracil + adriamycin + methotrexate; T: etoposide + leucovorin + fluorouracil; U: fluorouracil + leucovorine + irinotecan; V: etoposide + cisplatin + capecitabine; W: fluorouracil + leucovorin + cisplatin; X: cisplatin + etoposide + leucovorin + fluorouracil; a: DCR; b: ORR)](oncotarget-08-37896-g002){#F2}

Pooled results of network meta-analysis {#s2_3}
---------------------------------------

### Inconsistency test of DCR and ORR in included studies {#s2_3_1}

Design-by-treatment interaction model was used for the inconsistency test of DCR and ORR, the Wald test showed that all direct evidence and indirect evidence were consistent, and the fixed effect model was adopted (DCR: *P* = 0.7428, ORR: *P* = 0.2420).

Comparisons of DCR in different chemotherapy regimens {#s2_4}
-----------------------------------------------------

Totally 30 studies reported the differences of efficacy of DCR in AGC patients treated with twenty-four chemotherapy regimens. Network meta-analysis showed that as for single drug regimen, there was no significant difference for DCR in fluorouracil, S-1, and capecitabine chemotherapy regimens.

As for multi-drug combination regimen, AGC patients treated with CX, DCF and ECX chemotherapy regimens had better DCR when compared with CF chemotherapy regimen (CX: OR = 4.27, 95%CI = 1.05\~17.00; DCF : OR = 1.86, 95%CI = 1.05\~3.84; ECX: OR = 4.83, 95%CI = 1.39\~16.62), while the DCR of FAM chemotherapy regimens were relatively poorer (OR = 0.25, 95%CI = 0.13\~0.52) (Figure [3a](#F3){ref-type="fig"}).

![Forest plots of relationship for 24 kinds of chemotherapy regimens in terms of DCR and ORR (DCR = disease control rate; ORR = overall response rate; A: cisplatin + fluorouracil; B: fluorouracil; C: S-1; D: capecitabine; E: docetaxel + cisplatin; F: irinotecan + cisplatin; G: cisplatin + capecitabine; H: S-1 + cisplatin; I: docetaxel + fluorouracil; J: paclitaxel + fluorouracil; K: fluorouracil + leucovorin; L: docetaxel + oxaliplatin; M: S-1 + irinotecan; N: S-1 + paclitaxel; O: etoposide + adriamycin + cisplatin; P: docetaxel + cisplatin + fluorouracil; Q: etoposide + cisplatin + fluorouracil; R: fluorouracil + adriamycin + mitomycin; S: fluorouracil + adriamycin + methotrexate; T: etoposide + leucovorin + fluorouracil; U: fluorouracil + leucovorine + irinotecan; V: etoposide + cisplatin + capecitabine; W: fluorouracil + leucovorin + cisplatin; X: cisplatin + etoposide + leucovorin + fluorouracil; a: DCR; b: ORR)](oncotarget-08-37896-g003){#F3}

Compared with DC chemotherapy regimen, the DCR of ECX chemotherapy regimen was relatively good (OR = 4.03, 95%CI = 1.04\~16.78), while the DCR of FAM chemotherapy regimen was relatively poorer (OR = 0.22, 95%CI = 0.07\~0.68). The DCR of CX, S-1P and ECX chemotherapy regimens were relatively better than CI chemotherapy regimen (CX: OR = 5.59, 95%CI = 1.40\~23.76; S-1P: OR = 6.81, 95%CI = 1.27\~42.87; ECX: OR = 6.40, 95%CI= 1.50-26.1). The DCR of CF, CI, PF, FL, FAM, FAMTX, ELF and CELF chemotherapy regimens were relatively poorer than CX chemotherapy regimen (CF: OR = 0.23, 95%CI = 0.06\~0.95; CI: OR = 0.18, 95%CI = 0.04\~0.71; PF: OR = 0.17, 95%CI = 0.02\~0.89; FL: OR = 0.19, 95%CI = 0.04\~0.87; FAM: OR = 0.06, 95%CI = 0.01\~0.26; FAMTX: OR = 0.14, 95%CI = 0.04\~0.55; ELF: OR = 0.16, 95%CI = 0.04\~0.67; CELF: OR = 0.19, 95%CI = 0.04\~0.90).

Compared with S-1C chemotherapy regimen, the DCR of FAM, FAMTX and ELF chemotherapy regimens were relatively poorer (FAM: OR = 0.08, 95%CI = 0.02\~0.41; FAMTX: OR = 0.19, 95%CI = 0.05\~0.85; ELF: OR = 0.22, 95%CI = 0.05\~0.96). The DCR of ECX chemotherapy regimen was relatively better than DF chemotherapy regimen (OR = 4.54, 95%CI = 1.27\~20.81). The DCR of CX, S-1P and ECX chemotherapy regimens were relatively better than PF chemotherapy regimen (CX: OR = 5.90, 95%CI = 1.12\~43.52; S-1P: OR = 6.73, 95%CI = 1.09\~63.93; ECX: OR = 6.22, 95%CI = 1.31\~41.92). Compared with FL chemotherapy regimen, the DCR of CX, S-1P, ECX and FLC chemotherapy regimens were relatively better (CX: OR = 5.21, 95%CI = 1.15\~25.77; S-1P : OR = 6.27, 95%CI = 1.02\~45.52; ECX: OR = 5.68, 95%CI = 1.43\~25.94; FLC: OR = 2.41, 95%CI = 1.12\~5.28), while the DCR of FAM chemotherapy regimen was relatively poorer (OR = 0.31, 95%CI = 0.10\~0.87).

The DCR of FAM chemotherapy regimen was relatively poorer than DO chemotherapy regimen (OR = 0.12, 95%CI = 0.02\~0.60); and the DCR of FAM and FAMTX chemotherapy regimens were relatively poorer than S-1I chemotherapy regimen (FAM: OR = 0.06, 95%CI = 0.01\~0.41; FAMTX: OR = 0.14, 95%CI = 0.02\~0.91). Compared with S-1P chemotherapy regimen, the DCR of CI, PF, FL, FAM, FAMTX and ELF chemotherapy regimens were relatively poorer (CI: OR = 0.15, 95%CI = 0.02\~0.79; PF: OR = 0.15, 95%CI = 0.02\~0.92; FL: OR = 0.16, 95%CI = 0.02\~0.98; FAM: OR = 0.05, 95%CI = 0.01\~0.30; FAMTX: OR = 0.11, 95%CI = 0.02\~0.64; ELF: OR = 0.13, 95%CI = 0.02\~0.77). The DCR of FAM chemotherapy regimen was relatively poorer than EAC chemotherapy regimen (OR = 0.18, 95%CI = 0.04\~0.84). The DCR of CF, FAM, FAMTX and ELF chemotherapy regimens were relatively poorer than DCF chemotherapy regimen (CF: OR = 0.54, 95%CI = 0.26\~0.95; FAM: OR = 0.13, 95%CI = 0.05\~0.31; FAMTX: OR = 0.31, 95%CI = 0.14\~0.67; ELF: OR = 0.35, 95%CI = 0.14\~0.83).

Compared with ECF chemotherapy regimen, the DCR of FAM, FAMTX and ELF chemotherapy regimens were relatively poorer (FAM: OR = 0.14, 95%CI = 0.06\~0.35; FAMTX: OR = 0.34, 95%CI = 0.17\~0.67; ELF: OR = 0.37, 95%CI = 0.15\~0.93). Compared with FLI chemotherapy regimen, the DCR of ECX chemotherapy regimen was relatively better (OR = 3.82, 95%CI = 1.06\~14.81), while the DCR of FAM chemotherapy regimen was relatively poorer (OR = 0.20, 95%CI = 0.08\~0.54). The DCR of FL, FAM and FAMTX chemotherapy regimens were relatively poorer than FLC chemotherapy regimen (FL: OR = 0.41, 95%CI = 0.19\~0.89; FAM: OR = 0.13, 95%CI = 0.05\~0.38; FAMTX: OR = 0.29, 95%CI = 0.10\~0.88). The comparisons of DCR in different chemotherapy regimens are showed in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

Comparisons of ORR in different chemotherapy regimens {#s2_5}
-----------------------------------------------------

The differences in the ORR of twenty-four chemotherapy regimens in the treatment of AGC were reported in 35 studies. Network meta-analysis revealed that as for single drug regimen, there was no significant difference for ORR in fluorouracil, S-1, and capecitabine chemotherapy regimens. As for multi-drug combination regimen, AGC patients treated with CX, PF, DCF and ECF chemotherapy regimens had better efficacy when compared with CF chemotherapy regimen (CX: OR = 2.18, 95%CI = 1.24\~3.86; PF: OR = 4.53, 95%CI = 1.34\~18.38; DCF: OR = 2.25, 95%CI = 1.28-4.49; ECF: OR = 2.27, 95%CI = 1.24-4.50), while FAM chemotherapy regimen had poorer efficacy (FAM: OR = 0.21, 95%CI = 0.10\~0.43) (Figure [3b](#F3){ref-type="fig"})

The ORR of FAM chemotherapy regimen was relatively poorer than DC chemotherapy regimen (OR = 0.14, 95%CI = 0.04\~0.44). Compared with CI chemotherapy regimen, the ORR of CX, S-1C, DF, PF, DCF, ECF and ECX chemotherapy regimen was relatively better (CX: OR = 3.49, 95%CI = 1.29\~10.46; S-1C: OR = 3.18, 95%CI = 1.20\~8.83; DF: OR = 4.44, 95%CI = 1.13\~20.04; PF: OR = 7.30, 95%CI = 1.69\~38.97; DCF: OR = 3.59, 95%CI = 1.26\~12.18; ECF: OR = 3.64, 95%CI = 1.28-11.81; ECX: OR = 3.34, 95%CI = 1.01-12.46). Compared with CX chemotherapy regimen, the ORR of CF, CI, FL, FAM, FAMTX and ELF chemotherapy regimen was relatively poorer (CF: OR = 0.46, 95%CI = 0.26\~0.81; CI: OR = 0.29, 95%CI = 0.10\~0.78; FL: OR = 0.19, 95%CI = 0.06\~0.61; FAM: OR = 0.10, 95%CI = 0.04\~0.23; FAMTX: OR = 0.38, 95%CI = 0.18\~0.85; ELF: OR = 0.22, 95%CI = 0.07\~0.59).

The ORR of CI, FL, FAM and ELF chemotherapy regimens were relatively poorer than S-1C chemotherapy regimen (CI: OR = 0.31, 95%CI = 0.11\~0.83; FL: OR = 0.21, 95%CI = 0.07\~0.68; FAM: OR = 0.11, 95%CI = 0.04\~0.28; ELF: OR = 0.24, 95%CI = 0.08\~0.70). The ORR of CI, FL, FAM, FAMTX and ELF chemotherapy regimens were relatively poorer than DF chemotherapy regimen (CI: OR = 0.23, 95%CI = 0.05\~0.88; FL: OR = 0.15, 95%CI = 0.03\~0.61; FAM: OR = 0.08, 95%CI = 0.02\~0.25; FAMTX: OR = 0.30, 95%CI = 0.09\~0.91; ELF: OR = 0.17, 95%CI = 0.04\~0.65). Compared with PF chemotherapy regimen, the ORR of CF, CI, FL, EAC, FAM, FAMT and ELF chemotherapy regimen were relatively poorer (CF: OR = 0.22, 95%CI = 0.05\~0.75; CI: OR = 0.14, 95%CI = 0.03\~0.59; FL: OR = 0.09, 95%CI = 0.02\~0.43; EAC: OR = 0.21, 95%CI = 0.04\~0.96; FAM: OR = 0.05, 95%CI = 0.01\~0.18; FAMTX: OR = 0.18, 95%CI = 0.04\~0.66; ELF: OR = 0.11, 95%CI = 0.02\~0.44).

Compared with FL chemotherapy regimen, the ORR of CX, S-1C, DF, PF, S-1P, DCF, ECF, FLI, ECX and FLC chemotherapy regimens were relatively better (CX: OR = 5.34, 95%CI = 1.65\~17.11; S-1C: OR = 4.78, 95%CI = 1.47\~15.37; DF: OR = 6.74, 95%CI = 1.65\~29.06; PF: OR = 10.94, 95%CI = 2.33\~60.45; S-1P: OR = 4.84, 95%CI = 1.01\~20.27; DCF: OR = 5.42, 95%CI = 1.85\~18.24; ECF: OR = 5.55, 95%CI = 1.84\~17.86; FLI: OR = 2.77, 95%CI = 1.08\~6.94; ECX: OR = 5.16, 95%CI = 1.39\~19.25; FLC: OR = 2.53, 95%CI = 1.15\~5.47). The ORR of FAM chemotherapy regimen was relatively poorer than DO chemotherapy regimen (OR = 0.12, 95%CI = 0.02\~0.57). The ORR of FAM chemotherapy regimen was also poorer than S-1I chemotherapy regimen (OR = 0.12, 95%CI = 0.03\~0.55). Compared with S-1P chemotherapy regimen, the ORR of FL, FAM and ELF chemotherapy regimens were relatively poorer (FL: OR = 0.21, 95%CI = 0.05\~0.99; FAM: OR = 0.11, 95%CI = 0.03\~0.40; ELF: OR = 0.25, 95%CI = 0.06\~0.95). Compared with EAC chemotherapy regimen, the ORR of PF chemotherapy regimen was relatively better (OR = 4.75, 95%CI = 1.04\~24.22), while the ORR of FAM chemotherapy regimen was relatively poorer (OR = 0.22, 95%CI = 0.08\~0.58). The ORR of CF, CI, FL, FAM, FAMTX and ELF chemotherapy regimens were relatively poorer than DCF chemotherapy regimen (CF: OR = 0.44, 95%CI = 0.22\~0.78; CI : OR = 0.28, 95%CI = 0.08\~0.79; FL: OR = 0.18, 95%CI = 0.05\~0.54; FAM: OR = 0.09, 95%CI = 0.04\~0.22; FAMTX: OR = 0.36, 95%CI = 0.17\~0.76; ELF: OR = 0.22, 95%CI = 0.07\~0.55).

The ORR of CF, CI, FL FAM, FAMTX and ELF chemotherapy regimens were relatively poorer than ECF chemotherapy regimen (CF: OR = 0.44, 95%CI = 0.22\~0.81; CI : OR = 0.27, 95%CI = 0.08\~0.78; FL: OR = 0.18, 95%CI = 0.06\~0.54; FAM: OR = 0.09, 95%CI = 0.04\~0.21; FAMTX: OR = 0.35, 95%CI = 0.19\~0.68; ELF: OR = 0.21, 95%CI = 0.07\~0.53). Compared with FLI chemotherapy regimen, the ORR of FL, FAM and ELF chemotherapy regimens were relatively poorer (FL: OR = 0.36, 95%CI = 0.14\~0.93; FAM: OR = 0.19, 95%CI = 0.07\~0.53; ELF: OR = 0.41, 95%CI = 0.19\~0.97). Compared with FLC chemotherapy regimen, the DCR of FL and FAM chemotherapy regimens were relatively poorer (FL: OR = 0.40, 95%CI = 0.18\~0.87; FAM: OR = 0.21, 95%CI = 0.06\~0.65). The comparisons of ORR in different chemotherapy regimens are displayed in detail in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}.

Surface under the cumulative ranking curves (SUCRA) curves for short-term efficacy of twenty-four chemotherapy regimens in the treatment of advanced gastric cancer {#s2_6}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, in the outcome of DCR, the chemotherapy regimens of S-1 and capecitabine was better than fluorouracil in terms of single drug regimen, while S-1P chemotherapy regimen had better efficacy for AGC patients with respect to multi-drug combination regimen. In the outcome of ORR, the chemotherapy regimens of S-1 and capecitabine was better than fluorouracil in terms of single drug regimen, while PF chemotherapy regimen had better efficacy for AGC patients with respect to multi-drug combination regimen.

###### SUCRA values of twenty four treatment modalities under two endpoint outcomes

  Treatment   SUCRA values   
  ----------- -------------- -------
  A           0.399          0.393
  B           0.051          0.033
  C           0.619          0.359
  D           0.546          0.330
  E           0.450          0.577
  F           0.277          0.246
  G           0.859          0.763
  H           0.756          0.712
  I           0.403          0.820
  J           0.283          0.934
  K           0.307          0.137
  L           0.655          0.655
  M           0.848          0.666
  N           0.900          0.705
  O           0.530          0.385
  P           0.659          0.767
  Q           0.616          0.780
  R           0.027          0.040
  S           0.184          0.317
  T           0.225          0.161
  U           0.496          0.477
  V           0.896          0.740
  W           0.674          0.437
  X           0.315          0.577

Notes: DCR = disease control rate; ORR = overall response rate; A: cisplatin + fluorouracil; B: fluorouracil; C: S-1; D: capecitabine; E: docetaxel + cisplatin; F: irinotecan + cisplatin; G: cisplatin + capecitabine; H: S-1 + cisplatin; I: docetaxel + fluorouracil; J: paclitaxel + fluorouracil; K: fluorouracil + leucovorin; L: docetaxel + oxaliplatin; M: S-1 + irinotecan; N: S-1 + paclitaxel; O: etoposide + adriamycin + cisplatin; P: docetaxel + cisplatin + fluorouracil; Q: etoposide + cisplatin + fluorouracil; R: fluorouracil + adriamycin + mitomycin; S: fluorouracil + adriamycin + methotrexate; T: etoposide + leucovorin + fluorouracil; U: fluorouracil + leucovorin + irinotecan; V: etoposide + cisplatin + capecitabine; W: fluorouracil + leucovorin + cisplatin; X: cisplatin + etoposide + leucovorin + fluorouracil.

Cluster analysis for short-term efficacy of twenty-four chemotherapy regimens in the treatment of advanced gastric cancer {#s2_7}
-------------------------------------------------------------------------------------------------------------------------

Cluster analysis was conducted for the SUCRA values of twenty-four chemotherapy regimens in the outcomes of DCR and ORR. The results of cluster analysis demonstrated that AGC patients treated with CX, ECX, S-1P and S-1I chemotherapy regimens had better efficacy (Figure [4](#F4){ref-type="fig"}). The SUCRA plots of CX, ECX, S-1P and S-1I chemotherapy regimens under different outcomes are showed in Figure [5a](#F5){ref-type="fig"}-[5d](#F5){ref-type="fig"}.

![Cluster analysis plots for 24 kinds of chemotherapy regimens in terms of DCR and ORR (DCR = disease control rate; ORR = overall response rate; A: cisplatin + fluorouracil; B: fluorouracil; C: S-1; D: capecitabine; E: docetaxel + cisplatin; F: irinotecan + cisplatin; G: cisplatin + capecitabine; H: S-1 + cisplatin; I: docetaxel + fluorouracil; J: paclitaxel + fluorouracil; K: fluorouracil + leucovorin; L: docetaxel + oxaliplatin; M: S-1 + irinotecan; N: S-1 + paclitaxel; O: etoposide + adriamycin + cisplatin; P: docetaxel + cisplatin + fluorouracil; Q: etoposide + cisplatin + fluorouracil; R: fluorouracil + adriamycin + mitomycin; S: fluorouracil + adriamycin + methotrexate; T: etoposide + leucovorin + fluorouracil; U: fluorouracil + leucovorine + irinotecan; V: etoposide + cisplatin + capecitabine; W: fluorouracil + leucovorin + cisplatin; X: cisplatin + etoposide + leucovorin + fluorouracil)](oncotarget-08-37896-g004){#F4}

![SUCRA plots for chemotherapy regimens of CX, ECX, S-1P and S-1I (a: cisplatin + capecitabine; b: etoposide + cisplatin + capecitabine; c: S-1+ paclitaxel; d: S-1 + irinotecan)](oncotarget-08-37896-g005){#F5}

DISCUSSION {#s3}
==========

The network meta-analysis results revealed that there was no significant difference for DCR and ORR in the chemotherapy regimens of fluorouracil, S-1 and capecitabine in terms of single drug regimen, while the results of SUCRA showed that the chemotherapy regimens of S-1 and capecitabine were better than fluorouracil. Various chemotherapeutic agents have been used for improving response rate (RR), progression-free survival (PFS), overall survival (OS), and quality of life in patients with AGC \[[@R51]\]. Fluorouracil-based chemotherapy is commonly used for AGC, which has been suggested to have a survival benefit in comparison with the best supportive care \[[@R31]\]. Study has shown that without the inconvenience and complications associated with central venous catheters for fluorouracil, capecitabine maintains a constant level of 5-FU, which is therefore expected to have improved efficacy and tolerability when compared with protracted infusion 5-FU \[[@R52]\]. In the 1990s, S-1, as an oral derivative of 5-FU, was produced for the treatment of GC. As a single agent, S-1 was expected to have a high response rate of 46%, which rapidly established itself as a standard treatment for GC in Japan and was also used widely in clinical practice \[[@R32]\]. The presence of these new generation agents could play important roles in improving patient outcomes, and presenting the access to establish novel chemotherapeutic strategies and personalized medicine, which would help for each individual to select the optimal therapy and dose based on both the tumor and the patient \[[@R53]\]. In consideration of the ORR, OS as well as safety results, J-L Lee in his study provided evidence that patients with AGC could benefit from capecitabine or S-1 monotherapy with minimal adverse events \[[@R54]\]. A subset analysis of the FLAGS trial demonstrated that S-1 seemed to have better efficacy than 5-FU in diffuse type GC \[[@R55]\]. Both capecitabine and S-1 are more tolerable than 5-FU, and has been shown to present antitumor activity against AGC \[[@R56]\]. To some extent, single agent chemotherapy could be regarded as a good and safe first-line treatment for AGC, and it can avoid the compounding effects of other agents when combination therapy is used.

The network meta-analysis clearly shows that multi-drug combination chemotherapy regimens based on capecitabine and S-1 might be the best chemotherapy regimen for AGC. Various attempts have been made since the 1970s, in order to improve the results of chemotherapy through using multi-drug combination chemotherapy regimens. Randomized trials that making comparisons between monotherapy with combination regimens have consistently indicated increased response rates and survival rates in favor of combination regimens \[[@R57]\]. A randomized phase III trial have compared the combinations of fluorouracil with other agents in AGC: infusional 5-FU plus cisplatin (FUP) vs etoposide, LV and 5-FU (ELF) vs 5-FU, doxorubicin and methotrexate (FAMTX) \[[@R46]\]. However, a chemotherapy combination containing infusional 5-FU has the disadvantage of implanting a central venous catheter, and this procedure increases the incidence of subsequent complications, the costs of treatment administration, and the level of discomfort for the patient. The oral fluoropyrimidines (capecitabine and S-1) have shown particular promise, which therefore have the potential to reduce the times of medical examinations related to intravenous injection (i.v.) administration, to reduce the necessary resources for the implantation of the i.v. device, as well as to eliminate catheter-related adverse events \[[@R58]\]. Koizumi W proposed that combined with other promising drugs (eg. cisplatin, irinotecan and taxanes), oral fluoropyrimidine-based combination therapy was suggested to yield good results, and especially, the combination of cisplatin and oral fluoropyrimidines showed high efficacy, which was expected to be a standard therapy for AGC \[[@R12]\]. When S-1 was combined with other cytotoxic drugs, such as irinotecan and cisplatin, it was found to be promising, with relatively favorable safety profiles and response rates of 50 % \[[@R59]\]. A randomized phase III study concerning cisplatin and capecitabine (CX) combination therapy in AGC patients showed that CX produced an ORR of 46% and a median PFS of 5.6 months, which were remarkably better than the poor results with FU/cisplatin (CF) regimen \[[@R60]\]. All these verified that multi-drug combination chemotherapy regimens based on capecitabine and S-1 showed better efficacy than that based on fluorouracil.

Our network meta-analysis offers several important insights: (1) this study is the first network meta-analysis comparing twenty-four chemotherapy regimens in the treatment of AGC, and it bears important clinical implications; (2) we formulated comprehensive search strategy for minimizing possibilities of publication bias; (3) the article referred to both direct and indirect comparisons; (3) the posterior probabilities of SUCRA were utilized to distinguish the slight differences in chemotherapy regimens. However, several limitations of this meta-analysis deserve comment: (1) the presence of missing data in some of the enrolled studies might bias the results; (2) there showed a slight difference in the baseline characteristics of included patients in this network meta-analysis because of different eligible criteria in these studies; (3) since the S-1 agents in enrolled studies were derived from Asian countries, the S-1 regimens are widely used for AGC in Japan \[[@R43]\]. Furthermore, the interethnic differences of capecitabine were observed in genetic changes, which resulting in different efficacy \[[@R34]\]. There might be a certain racial difference, and subgroup analysis could not be carried out for this reason. These limitations might lead to a slight reduction in the validity of our overall results.

The network meta-analysis clearly shows that multi-drug combination chemotherapy regimens based on capecitabine and S-1 might be the best chemotherapy regimen for AGC. However, due to the limitations in our study, our conclusion is needed to be confirmed by a more adequately designed study for future clinical applications.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

PubMed, Embase, Ovid, EBSCO and Cochrane Library were searched from the inception of each database to July 2015. The search was conducted using the combination of keywords and free words strategy, the terms included "chemotherapy", "pharmacotherapy", "cisplatin", "fluorouracil", "Capecitabine", "Docetaxel", "Paclitaxel", "Oxaliplatin", "S-1" and "gastric cancer", etc. A manual search was also performed for the reference lists of published articles, and literature searches were supplemented by perusing the reference lists of previous meta-analyses.

Inclusion, exclusion criteria and data extraction {#s4_2}
-------------------------------------------------

The inclusion criteria included: (1) study design should be randomized controlled trail (RCT); (2) operative methods included chemotherapy agents for the treatment of advanced gastric cancer (AGC) patients; (3) clinically diagnosed AGC patients who only treated with chemotherapy while without any surgical treatments; (4) end outcomes included disease control rate (DCR) and overall response rate (ORR). The exclusion criteria included: (1) studies with insufficient data; (2) non-RCTs, duplicated publications and AGC patients received surgical treatment or radiotherapy. Two reviewers extracted data from the enrolled studies using a specifically designed form. Additionally, a third reviewer was consulted if agreement could not be reached between these two reviewers.

Statistical analysis {#s4_3}
--------------------

First, we conducted pair-wise meta-analyses of direct evidence by using the random-effects model, which was supplemented with R version 3.2.1 and the Meta package. Second, random-effects network meta-analysis was performed with the gemtc package. Lu and Ades reported that by linking to Open BUGS, network meta-analysis models the relative effects fitting a generalized linear model (GLM) under the Bayesian framework \[[@R61]\]. The relative effects were converted to a probability, which could judge whether a treatment was best or worst, with the surface under the cumulative ranking (SUCRA) curve of each treatment \[[@R62]\] presented as a percentage, ranging from 0%\~100% (0%: worst; 100%: best). Based on SUCRA curve, the summary estimates were showed in league tables through ranking the treatments according to priority of the most significant influence on the outcome under consideration \[[@R62]\]. Our command of cluster rank was used in the production of clustered ranking plots in STATA. Outcome1 and outcome2 were regarded as the data variables which containing the SUCRA values for all the treatments in a network. The different colors referred to the estimated clusters, which were used to group the treatments in accordance with their similarity in terms of both outcomes. The concept of design-by-treatment interaction supplied a useful general framework to explore the inconsistency. Particularly, the application of design-by-treatment interactions successfully dealt with complications arising from the multi-arm trials in an evidence network \[[@R63]\]. Lu and Ades also described that a model motivated mainly by loop inconsistency. We provided all models by using mvmeta, which was a Stata (Stata Corp LP. College Station, TX, USA) macro conducted random-effects multivariate meta-regression by using the restricted maximum likelihood \[[@R64]\].

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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CF

:   cisplatin + fluorouracil

DC

:   docetaxel + cisplatin

CI

:   irinotecan + cisplatin

CX

:   cisplatin + capecitabine

S-1C

:   S-1 + cisplatin

DF

:   docetaxel + fluorouracil

PF

:   paclitaxel + fluorouracil

FL

:   fluorouracil + leucovorin

DO

:   docetaxel + oxaliplatin

S-1I

:   S-1 + irinotecan

S-1P

:   S-1 + paclitaxel

EAC

:   etoposide + adriamycin + cisplatin

DCF

:   docetaxel + cisplatin + fluorouracil

ECF

:   etoposide + cisplatin + fluorouracil

FAM

:   fluorouracil + adriamycin + mitomycin

FAMTX

:   fluorouracil + adriamycin + methotrexate

ELF

:   etoposide + leucovorin + fluorouracil

FLI

:   fluorouracil + leucovorin + irinotecan

ECX

:   etoposide + cisplatin + capecitabine

FLC

:   fluorouracil + leucovorin + cisplatin

CELF

:   cisplatin + etoposide + leucovorin fluorouracil
